OutSee raises £1.8M seed funding to expand therapeutic pipeline using predictive genomics
Cambridge, UK, 24 June 2025: OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced it has secured £1.8M in seed funding, led by Ahren Innovation Capital and with additional investment from Empirical Ventures, Kadmos Capital and Panacea Investment Group. The funds will support OutSee through the next phase of its growth strategy, with a focus on expanding the Company’s in-house target discovery program and establishing new strategic partnerships with leading pharma and biotech companies.
Invented by Dr Julian Gough, CEO and Founder, OutSee’s proprietary Nomaly technology predicts disease and phenotype ab initio directly from a single genome. Unlike other methods commonly used for target discovery, the AI-powered engine uses hypothesis-free, predictive modelling to draw conclusions from the fundamental molecular and cellular biology of the genome, rather than by pattern-matching known genetic associations.
This unique ‘genomics first’ approach enables Nomaly to complement existing target discovery pipelines, uncovering underlying biological mechanisms that drive and modulate disease. Nomaly can be applied to small datasets, or to unlock new, actionable insights from data that has already been analysed, helping to advance therapeutic discovery and development. The technology has been
developed for use across a broad range of application areas, with OutSee’s in-house program initially focussed on CNS, rare and metabolic disease.
OutSee has previously received over £500k in precision medicine grants from Innovate UK to support
technology extensions and to test their application on dementia case studies.
“OutSee’s Nomaly technology is a truly next-generation genomic analysis tool with potential to transform drug discovery using powerful data-driven insights. It allows us to interrogate smaller datasets, and even data that has already been analysed, to uncover unique target insights that until now would have remained undetected.” commented Dr Julian Gough, CEO and Founder, OutSee. “I would like to thank our investors, whose support in this endeavour will be crucial in allowing us to build out our in-house target identification program and establish new collaborative partnerships, and to our team for their continued hard work and dedication.”
Dr Paul Wallace, Chair, OutSee, said: “I would like to thank our investors and partners for their support, and for their confidence in our mission to drive therapeutic discovery through our pioneering, genetics first predictive genomics approach. This funding will enable us to leverage the full potential of Nomaly to uncover new therapeutic targets and bolster our in-house pipeline. We remain open to additional investment opportunities, and welcome enquiries from interested pharma and biotech industry partners.”
Ahren Innovation Capital, remarked: “Outsee’s genomics first approach goes far beyond existing technologies, enabling therapeutic developers to precisely comb their data in a way that has never before been possible. Nomaly has great potential to unlock a deeper understanding of genomic data, discover new therapeutic targets and drive the development of next-generation treatments for the entire spectrum of human disease. I look forward to seeing OutSee’s continued growth and success, and to working closely with Julian and the team to support them through this journey.”
Dr Johnathan Matlock, Co-Founder and General Partner, Empirical Ventures, said: “At Empirical Ventures, we’re seeking out companies that push beyond the boundaries of conventional methods in their fields to significantly enhance the real-world impact of these industries. It’s for this reason that we are delighted to be supporting the team at Outsee as it advances a solution that will unlock the future of target ID for drug discovery. The entrepreneurial drive and deep expertise of the team, under Julian’s leadership, position Outsee at the forefront of this important progress in the drug discovery industry, with its work capable of redefining the treatment of patients suffering from devastating diseases.
